185 related articles for article (PubMed ID: 1982639)
21. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone.
Kamath N; Grabowski D; Ford J; Kerrigan D; Pommier Y; Ganapathi R
Biochem Pharmacol; 1992 Sep; 44(5):937-45. PubMed ID: 1356339
[TBL] [Abstract][Full Text] [Related]
22. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.
Tiberghien F; Loor F
Anticancer Drugs; 1996 Jul; 7(5):568-78. PubMed ID: 8862725
[TBL] [Abstract][Full Text] [Related]
23. Molecular mechanisms of multidrug resistance in cancer chemotherapy.
Nooter K; Stoter G
Pathol Res Pract; 1996 Jul; 192(7):768-80. PubMed ID: 8880878
[TBL] [Abstract][Full Text] [Related]
24. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals.
Borst P; Schinkel AH; Smit JJ; Wagenaar E; Van Deemter L; Smith AJ; Eijdems EW; Baas F; Zaman GJ
Pharmacol Ther; 1993 Nov; 60(2):289-99. PubMed ID: 7912835
[TBL] [Abstract][Full Text] [Related]
25. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes.
Twentyman PR; Rhodes T; Rayner S
Eur J Cancer; 1994; 30A(9):1360-9. PubMed ID: 7999426
[TBL] [Abstract][Full Text] [Related]
26. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells.
Anuchapreeda S; Leechanachai P; Smith MM; Ambudkar SV; Limtrakul PN
Biochem Pharmacol; 2002 Aug; 64(4):573-82. PubMed ID: 12167476
[TBL] [Abstract][Full Text] [Related]
27. Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias.
Gekeler V; Frese G; Noller A; Handgretinger R; Wilisch A; Schmidt H; Muller CP; Dopfer R; Klingebiel T; Diddens H
Br J Cancer; 1992 Sep; 66(3):507-17. PubMed ID: 1355660
[TBL] [Abstract][Full Text] [Related]
28. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Jonsson B; Nilsson K; Nygren P; Larsson R
Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
[TBL] [Abstract][Full Text] [Related]
29. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
Jensen PB; Christensen IJ; Sehested M; Hansen HH; Vindeløv L
Br J Cancer; 1993 Feb; 67(2):311-20. PubMed ID: 8094293
[TBL] [Abstract][Full Text] [Related]
30. Constitutive expression of multidrug resistance in human colorectal tumours and cell lines.
Kramer R; Weber TK; Morse B; Arceci R; Staniunas R; Steele G; Summerhayes IC
Br J Cancer; 1993 May; 67(5):959-68. PubMed ID: 8098614
[TBL] [Abstract][Full Text] [Related]
31. A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance.
Minderman H; Vanhoefer U; Toth K; Minderman MD; Rustum YM
Cancer; 1996 Dec; 78(11):2427-36. PubMed ID: 8941015
[TBL] [Abstract][Full Text] [Related]
32. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells.
Versantvoort CH; Schuurhuis GJ; Pinedo HM; Eekman CA; Kuiper CM; Lankelma J; Broxterman HJ
Br J Cancer; 1993 Nov; 68(5):939-46. PubMed ID: 8105867
[TBL] [Abstract][Full Text] [Related]
33. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs.
Chaudhary PM; Roninson IB
J Natl Cancer Inst; 1993 Apr; 85(8):632-9. PubMed ID: 8096875
[TBL] [Abstract][Full Text] [Related]
34. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1.
Abe T; Koike K; Ohga T; Kubo T; Wada M; Kohno K; Mori T; Hidaka K; Kuwano M
Br J Cancer; 1995 Aug; 72(2):418-23. PubMed ID: 7640227
[TBL] [Abstract][Full Text] [Related]
35. Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR.
Mariani M; Capolongo L; Suarato A; Bargiotti A; Mongelli N; Grandi M; Beck WT
Invest New Drugs; 1994; 12(2):93-7. PubMed ID: 7860237
[TBL] [Abstract][Full Text] [Related]
36. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
Hasegawa S; Abe T; Naito S; Kotoh S; Kumazawa J; Hipfner DR; Deeley RG; Cole SP; Kuwano M
Br J Cancer; 1995 May; 71(5):907-13. PubMed ID: 7734314
[TBL] [Abstract][Full Text] [Related]
37. Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines.
Herzog CE; Trepel JB; Mickley LA; Bates SE; Fojo AT
J Natl Cancer Inst; 1992 May; 84(9):711-6. PubMed ID: 1349044
[TBL] [Abstract][Full Text] [Related]
38. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
39. Characterization of an etoposide-resistant human small-cell lung cancer cell line.
Minato K; Kanzawa F; Nishio K; Nakagawa K; Fujiwara Y; Saijo N
Cancer Chemother Pharmacol; 1990; 26(5):313-7. PubMed ID: 1976450
[TBL] [Abstract][Full Text] [Related]
40. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance.
Utz I; Hofer S; Regenass U; Hilbe W; Thaler J; Grunicke H; Hofmann J
Int J Cancer; 1994 Apr; 57(1):104-10. PubMed ID: 7908658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
